Teva Announces Launch of Generic Viagra

Teva Pharmaceutical Industries has announced the US launch of their generic sildenafil citrate (Viagra) tablets, according to a company press release.

Sildenafil tablets are a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED).

Additionally, officials with Teva are offering a sildenafil tablets savings card for patients who meet certain requirements, allowing them to pay as little as $0 out-of-pocket cost with a maximum benefit of up to $100 per fill, for up to 6 sildenafil tablets prescriptions.

According to its safety information, sildenafil tablets should not be used in men for whom sexual activity is inadvisable due to their underlying cardiovascular status, since the medication can cause cardiac risk. Concomitant use of sildenafil tablets and alpha-blockers or anti-hypertensives may lead to hypotension. Concomitant administration of sildenafil tablets and the protease inhibitor ritonavir substantially increases serum concentrations of sildenafil.

Common adverse reactions associated with sildenafil tablets include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness, and rash.

In July, officials with Greenstone LLC announced they too would be offering sildenafil citrate in strengths of 25 mg; 50 mg; and 100 mg, once Viagra lost its exclusivity this month.

Reference

Teva Announces Exclusive Launch of Generic Viagra Tablets in the United States [news release]. Teva’s website. http://www.tevapharm.com/news/teva_announces_exclusive_launch_of_generic_viagra_tablets_in_the_united_states_12_17.aspx. Accessed December 11, 2017.